ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study
By Don Nico Forbes
Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung cancer.
Shares were up 22% in premarket trading at $20.40. The stock is up more than 52% this year.
The biopharmaceutical company said follow-up interim data from the Phase 2 study, sponsored by British pharmaceutical firm GSK, showed a clinically meaningful objective response rate of 63.3% to 76.7% for PD-L1 high non-small cell lung cancer patients.
This represents a more than 30% improvement compared with a treatment of dostarlimab alone, iTeos said.
iTeos said the data supports the recent initiation of Phase 3 trials.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
September 16, 2024 06:43 ET (10:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States